Baseline and long‐term longitudinal atrophy patterns of cognitively unimpaired individuals with elevated plasma ptau‐217

Abstract

Background: Plasma p ‐tau217 is an emerging biomarker for Alzheimer’s disease (AD) and has been shown to be a strong predictor of cognitive decline even in cognitively unimpaired (CU) individuals. However, little is known about the association of elevated plasma p ‐tau217 with long‐term neurodegenerative trajectories.